According to a study by Coherent market Insights, and is expected to grow at a CAGR of 11.3% in terms of revenue over the forecast period (2024-2031). Mr. Shah Coherent Market Insights Pvt. Ltd. +1 ...

The 108-week open-label extension period (Part C) to evaluate longer-term outcomes was recently completed. Results from the trial were published in The New England Journal of Medicine. Dupixent is an ...